• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Application of 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid (CAS: 171557-31-6) in Chemical Biology and Pharmaceutical Research

The compound 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid (CAS: 171557-31-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, mechanism of action, and potential therapeutic applications.

Recent studies have highlighted the role of 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid as a key intermediate in the synthesis of peptide-based therapeutics. Its unique structural features, including the tert-butoxy groups, make it an ideal candidate for protecting amino acids during solid-phase peptide synthesis (SPPS). A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in improving the yield and purity of complex peptide sequences, particularly those targeting G-protein-coupled receptors (GPCRs).

In addition to its synthetic utility, this compound has shown promise in the development of novel prodrugs. Research conducted at the University of Cambridge in 2024 revealed that 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid can be used to enhance the bioavailability of poorly soluble drugs by forming ester prodrugs. The study reported a 2.5-fold increase in oral absorption for a model anticancer drug when conjugated with this compound, suggesting its potential for improving drug delivery systems.

Another significant advancement involves the application of this compound in targeted drug delivery. A team at MIT recently developed a nanoparticle-based system where 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid serves as a linker between the nanoparticle core and therapeutic payload. This system demonstrated enhanced tumor targeting and reduced off-target effects in preclinical models of breast cancer, as reported in Nature Nanotechnology (2024).

From a mechanistic perspective, computational studies have provided insights into the molecular interactions of this compound. Molecular dynamics simulations published in the Journal of Chemical Information and Modeling (2023) revealed that the tert-butoxy groups contribute to the compound's stability in physiological conditions while allowing for controlled release of active pharmaceutical ingredients through enzymatic cleavage.

Looking forward, researchers are exploring the potential of 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid in emerging areas such as PROTAC (proteolysis-targeting chimera) technology and antibody-drug conjugates (ADCs). Preliminary results from a collaboration between Pfizer and Stanford University suggest that this compound could serve as an effective linker in next-generation ADCs, with improved stability and reduced immunogenicity compared to current technologies.

In conclusion, the growing body of research on 2-(Bis(2-(tert-butoxy)-2-oxoethyl)amino)acetic acid (CAS: 171557-31-6) underscores its importance as a multifunctional tool in modern pharmaceutical research. Its applications span from synthetic chemistry to advanced drug delivery systems, making it a compound of significant interest for future therapeutic development. Continued research in this area is expected to yield further innovations in drug design and delivery strategies.

• 644985-63-7(Glycine, N,N-bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-, ethyl ester)
• 122555-91-3(DO3A tert-Butyl ester)
• 162148-48-3(tert-butyl 2-[7-(2-tert-butoxy-2-oxo-ethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate)
• 137076-54-1(DOTA-tri(t-butyl ester))
• 137145-75-6(1,4,7,10-Tetraazacyclododecane-1-acetic acid, 1,1-dimethylethyl ester)
• 507475-91-4(1,4,7,10-Tetraazacyclododecane-1,4-diacetic acid, 1,4-bis(1,1-dimethylethyl) ester)
• 585531-74-4(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,tetrakis(1,1-dimethylethyl) ester)
• 824984-75-0(1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(2-aMinoethyl)-, tris(1,1-diMethylethyl) ester)
• 88217-68-9(4-Morpholineacetic acid, 1,1-dimethylethyl ester)
• 825625-07-8(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,tris(1,1-dimethylethyl) ethyl ester)